Aptadir raises €40 million Seed to advance RNA therapeutics

Targeted RNA against gene silencing

Aptadir’s aptaDiR molecules bind and inhibit DNMT1. Its captaDiR design adds a gene-specific sequence to direct the inhibitor toward a selected locus, with the aim of restoring expression of genes silenced in disease.

A pipeline led by Fragile X syndrome

The lead investigational program, CAP1-FMR1, targets Fragile X syndrome, where the FMR1 gene is silenced. The company is advancing this and other rare-disease and cancer programs at the preclinical stage.

Use of funds

Advance the pipeline of investigational RNA therapeutics, including CAP1-FMR1 for Fragile X syndrome

Funding history

Sep 29, 2026Seed · This round€40M

Sources

Similar rounds

All Biotech rounds →

General Medicine

An online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.

$120MSeries B · Oct 6, 2026

Blue Health Intelligence

Blue Health Intelligence combines a one-hour health assessment with doctor-led interpretation and a digital plan for preventive care.

€3.4M€3.4 million growth capital · Sep 30, 2026

mutex

Medical billing software that helps hospital and clinic staff identify missed charges and errors before submitting claims.

¥281.6MSeries A · Sep 30, 2026

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026